Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
H. Lundbeck
Biotech
Lundbeck cans schizophrenia trial effort as drug comes up shorts
Creating new, successful central nervous system drugs is tough, and Lundbeck knows this better than most after canning an internal CNS effort.
Ben Adams
Aug 6, 2020 7:33am
Lundbeck plotting up to 160 R&D cuts as it rebuilds pipeline
Jun 9, 2020 7:50am
Lundbeck pens $2B Alder takeover to boost brain disease pipeline
Sep 16, 2019 6:17am
Lundbeck strikes $250M Abide buyout, bagging Tourette's drug
May 6, 2019 8:22am
Lundbeck and Otuska’s brexpiprazole hits the mark in PTSD trial
Nov 30, 2018 8:49am
Lundbeck schizophrenia drug fails phase 3, sinking stock
Oct 26, 2018 10:20am
